Overview

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2011-02-08

Target enrollment:

Participant gender:

Summary

The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Fluticasone